By David M. Ullian
Mar 5, 2025
Cannabis-related legislation is once again on the move in South Carolina with the filing of a bill that would establish a regulated medical cannabis program and several bills that would officially regulate consumable products containing hemp-derived cannabinoids, including the increasingly popular beverages containing hemp-derived Delta-9 THC.
By Juliana Todeschi, Joshua Kappel
Mar 4, 2025
Colorado’s Natural Medicine Division has finalized its Environmental, Social, and Governance (ESG) requirements for Natural Medicine Business licensing. These guidelines help applicants create plans that promote sustainability, social impact, and ethical governance. Notably, the rules emphasize honoring Indigenous communities and ensuring transparency in business operations.
By Meg Nash, Casey Leaver
Feb 18, 2025
Catch up on the current state of Rhode Island's cannabis market, regulatory enforcement trends, highlights from the proposed adult-use rules, and the anticipated cannabis business licensing opportunities on the horizon.
By Charles Alovisetti
Feb 11, 2025
Startups and growing businesses need capital, but should they accept funds from anyone willing to invest? The answer: probably not. In fact, choosing the right investors—particularly accredited investors—can save you time, money, and future headaches. In this Insights post, we discuss what to look for when selecting an investor and the risks of raising funds from unaccredited investors, including disclosure agreements, preemptive rights issues and IPO complications. Plus, considerations when deciding to work with investors outside of the United States.
By Shawn Hauser, Andrew Livingston
Jan 31, 2025
The much-anticipated hearings on the proposed rulemaking to reschedule cannabis, which were scheduled to begin on January 21, have been postponed for at least three months as a result of an appeal granted by DEA Administrative Law Judge John Mulrooney. In this article, we examine a timeline of progress on rescheduling so far and discuss what may happen next and how the new administration may affect the process.
Commentary and analysis on cannabis, hemp, psychedelics, and other emerging therapies from the attorneys and policy specialists at the nation’s leading cannabis law firm.